Newlink genetics launches phase i clinical trial

NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.12/20/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news